EBRO 2017

Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis Bourhis et al. Lancet 2006; 368: 843-854

•

Fifteen trials with 6515 patients included

•

Mainly oropharynx and larynx tumors

•

74% of patients had stage III-IV disease

•

Three categories:

hyperfractionated accelerated accelerated with total dose reduction

•

Data were collected for individual patients.